Skip to main content

Table 2 Best overall response by criteria.

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Criteria Response/Evaluable % (95% CI)
PSA 5/22 23 (8–45)
Measurable 0/8 0 (0–31)
Bone disease 1/20 5 (0–25)